Assessing Grifols (BME:GRF) Valuation After H1 2025 Results And Dividend Reinstatement

Grifols (BME:GRF) has drawn fresh attention after its H1 2025 update, reporting €3.7b in revenue, higher adjusted EBITDA, reaffirmed full year guidance, a stronger free cash flow outlook and a reinstated interim dividend.

See our latest analysis for Grifols.

Despite the solid H1 2025 update, the share price has had a weak run, with a 30 day share price return of 5.72% and a 90 day share price return showing a 21.56% decline, while the 1 year total shareholder return of 15.18% reflects a stronger longer term outcome for investors who stayed invested.

If this earnings story has you rethinking healthcare exposure, it can be useful to see what else is out there in the sector, including emerging names in medical AI. You can scan the market for new ideas using our healthcare focused 123 healthcare AI stocks

So with Grifols trading after a weak recent share price run but carrying analyst targets and intrinsic estimates above the current price, should you see a valuation gap here, or assume the market is already pricing in future growth?

Most Popular Narrative: 40.7% Undervalued

Grifols closed at €8.93, while the most followed narrative sets fair value around €15.08, implying a sizeable valuation gap that hinges on execution and cash generation over time.

Disciplined cost management, deleveraging efforts, and normalization of business operations are strengthening Grifols' balance sheet and enabling higher free cash flow generation, supporting reinvestment and the resumption of shareholder returns, positively impacting net margins and overall earnings quality.

Read the complete narrative.

Want to see what earnings path and margin profile sit behind that higher fair value? The narrative leans on measured growth, firmer profitability and a richer future earnings multiple.

Result: Fair Value of €15.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on high leverage and pressure in key markets like China not eroding margins or restricting the cash generation needed to support the thesis.

Find out about the key risks to this Grifols narrative.

Next Steps

With sentiment split between risk and reward, it makes sense to move quickly, review the data for yourself and weigh up the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your style. Take a few minutes to scan these focused stock lists:

• Target potential upside with companies that combine quality and attractive pricing by running your filters through our 231 high quality undervalued stocks
• Prioritize resilience and capital strength by zeroing in on companies highlighted in our solid balance sheet and fundamentals stocks screener (389 results)
• Spot lesser known opportunities before they get crowded by checking the screener containing 574 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com